

Cell recognition and the immune system 2

Level: CIE AS 9700 Subject: Biology Exam Board: Suitable for all boards Topic: Cell recognition and the immune system 2 Type: Mark Scheme

To be used by all students preparing for CIE AS Biology 9700 foundation or higher tier but also suitable for students of other boards.



Mark schemes

| 1 | (a) | A = envelope/membrane/phospholipid (bilayer); B = capsid / nucleocapsid / capsomere / protein; 2 | |
|---|-----|--|---|
| | | (i) (HIV is) invading cells which make new viruses; Cells release viruses into blood; | |
| | | (ii) Virus remains dormant/exists as provirus/exists as DNA in host DNA; Accept virus stays in cells | |
| | (c) | HIV destroys T cells; More (free) viruses produced leads to fall in T-cells; (So fewer) T-cells activate B-cells/memory cells; | |
| | | Reduced/no antibody production; Immune system not working properly/inability to fight infection; Opportunistic infections; | |
| | | 4 max | |
| 2 | (a) | Nucleus; | 1 |
| | (b) | Enables organism to remain in area (of food source) / prevent its removal; Q To attach' is not sufficient unless qualified | 1 |
| | (c) | (i) Correct answer of 222(%);; | |
| | | Incorrect answer that clearly identifies difference in number of cases as $5800 - 1800$ or $5.8 - 1.8$; | |
| | | Correct answer gains two marks | 2 |
| | | More water-related activities / more 'organisms' with increased temperature; <i>Q</i> Allow any reference to growth or replication of 'organisms'. Do not penalise reference to bacteria. | |
| | | Q Do not allow increase in water consumption. | 1 |
| | (d) | (i) All have same shape / only binds to <i>Giardia</i> / one type of / specific antigen; | 1 |

[9]



| | (ii) | Has complementary (shape) / due to (specific) tertiary structure / variable region (of antibody); | | |
|-----|--|---|-------|------|
| | | Q Binds / fits not sufficient unless qualified; | 1 | |
| | (iii) | Enzyme / second antibody would remain / is removed by washing; | | |
| | | Enzyme can react with substrate (when no antigen is present); | 2 | [9] |
| (a) | Pha | gocytes engulf / ingest pathogens / microorganisms / bacteria / viruses; | | |
| | Pha | gocytes destroy pathogens / microorganisms / bacteria / viruses; | | |
| | Lung | diseases are caused by pathogens / microorganisms / bacteria / viruses; Q Allow description of process of engulfing | 2 max | |
| (b) | (i) | Alveoli / lungs will not inflate / deflate fully / reduced lung capacity; | | |
| | | Breathing out particularly affected / no longer passive; | 2 | |
| | (ii) | Alveolar walls thicken; | | |
| | | Longer <u>diffusion</u> pathway; | | |
| | | Scarred / fibrous tissue; | | |
| | | Reduces <u>surface area</u> (for gaseous exchange); | | |
| | | Q Diffusion is essential for 2^{nd} point and surface area for 4^{th} point. | 4 | |
| (c) | (i) | Cancer develops 20 – 30 years after exposure (to asbestos); | 1 | |
| | (ii) | Smoking / air pollution / specified industrial source; | 1 | [10] |
| (a) | Pha | gocytes engulf pathogens / microorganisms; | | |
| | Enclosed in a vacuole / vesicle / phagosome; | | | |
| | Lyso | somes have enzymes; | | |
| | That | digest / hydrolyse molecules / proteins / lipids / microorganism; | 3 max | |



| | (b) | (i) | Get another strain / there are different strains; | | |
|---|------|------|--|---|-----|
| | | | Therefore does not have memory cells against second strain; Q The second marking point should only be awarded in the context of memory cells. | 2 | |
| | | (ii) | Vaccines only work against certain strains because the antigens they possess are different; | 2 | |
| | | | Enables company to target strain likely to be prevalent later / most common strain; | 2 | |
| | | | | 2 | [7] |
| 5 | (a) | (i) | Many people do not go to the doctor; | 1 | |
| | | (ii) | 36000; | | |
| | | | No marks awarded for working here as calculation is very straightforward | | |
| | 41.5 | • | | 1 | |
| | (b) | Sam | ne sugars / antigens on bacteria / nerve cells; Do not accept references to same shape as equivalent to complementary. | | |
| | | Bind | l with antibody / form antigen-antibody complex; <i>Reject react</i> | | |
| | | Have | e complementary shape / fit binding site; <i>Reject active site</i> | | |
| | | | | 3 | |
| | (c) | Diap | ohragm will not move down / flatten / contract; Ignore references to breathing out | | |
| | | Tho | racic cavity / lung volume not increased so cannot breathe in; | 2 | [7] |
| 6 | (a) | | ecule / part of molecule / protein / glycoprotein / named molecule; stimulates an immune response / eq; | 2 | |
| | (b) | | de by mitosis / form clones; produce plasma cells; (plasma cells) e antibodies; | 2 | |
| | | | sma cells) produce memory cells; | 4 | |



| | (c) | (i) | glycoprotein AND different shape to body proteins / RNA and reverse transcriptase inside virus / phospholipids same as body's / on the surface of the virus; | 1 | |
|---|-----|---------------|--|-------|-----|
| | | (ii) | 187.5;; Accept 187 – 188 1 mark for HIV = 80nm; | 2 max | [9] |
| | (a) | proc (pla: | le by mitosis / form clones; luce plasma cells; sma cells) make antibodies; sma cells) produce memory cells; | 4 | |
| | (b) | diffe loca | oprotein; rent shape to body proteins / body phospholipids are the same / ted on the outside of the cell / the haemoglobin is located le the cell; | 2 | [6] |
| 7 | (a) | Injed | ction of antigens / toxoids; | | |
| | | | igen from) attenuated microorganism / non-virulent oorganisms / dead | | |
| | | micr | oorganisms / isolated from microorganism; | | |
| | | Stim | ulates the formation of memory cells; | max 2 | |
| | (b) | (i) | Antibodies are specific to mumps antigen; 2nd antibodies specific to mumps antibody; | 1 | |
| | | (ii) | Removes unbound 2 nd antibodies; Otherwise enzyme may be present / may get colour change anyway / false positive; | 2 | |
| | | (iii) | No antibodies to bind (to antigen); Therefore 2 nd antibody (with the enzyme) won't bind / no enzyme / enzyme-carrying antibody present (after washing in step 4); | | |
| | | | | 2 | [7] |



Г

Г

| 9 | (a) | Stimulates memory cells; | | |
|----|-----|---|-------|-----|
| | | Secondary response, so antivenom / antibodies produced quicker; | 2 | |
| | (b) | Passive immunity; so no memory cells produced; | | |
| | | Antivenom breaks down / destroyed; | 2 | |
| | (c) | Could transfer disease / Allergy / Immune response to antibodies from animal; | 1 | |
| | | | - | [5] |
| 10 | (a) | add antibodies / enzyme; wash to remove unbound antibodies; add (colourless) solution; | | |
| | | (mark correct responses sequentially) | 3 | |
| | (b) | antibodies specific / shape only fits one antigen; other antigens different shape and would not bind to antibodies; | | |
| | | | 2 | [5] |
| 11 | (a) | (i) protein / immunoglobulin; specific to antigen; idea of 'fit' / complementary <u>shape;</u> | 2 max | |
| | | (ii) 1. virus contains antigen; 2. virus engulfed by phagocyte / macrophage; 3. presents antigen to B-cell; 4. memory cells / B-cell becomes activated; 5. (divides to) form clones; 6. by mitosis; 7. plasma cells produce antibodies; 8. antibodies specific to antigen; 9. correct reference to T-cells / cytokines; | 6 max | |
| | (b) | antibody gene located using gene probe; cut using restriction enzyme; at specific base pairs; leaving sticky ends / unpaired bases; cut maize / DNA / vector using same restriction enzyme; join using DNA ligase; introduce vector into maize / crop / recombinant DNA into maize; | 4 max | |
| | | | | |



| | (c) | passive / person is not making own antibodies / antibodies not replaced; memory cells not produced; | 2 | |
|----|-----|--|-------|------|
| | (d) | fewer ethical difficulties / less risk of infection; | 1 | [15] |
| 12 | (a) | To prevent contamination of apparatus with other microorganisms / bacteria; To prevent personal contact with bacteria; To prevent release of bacteria into air; | | [10] |
| | (b) | (i) Diffuses slowly; | max 2 | |
| | | B; Produces inhibition zone greater than the minimum diameter; | 2 | [5] |
| 13 | (a) | Publicity about vaccination / better health education / risks of 'flu epidemics; (Accept: now free on NHS (though only since 2000) / better awareness / more commonly available) | 1 | [0] |
| | (b) | (i) 1990: 26% of 7.4million = 1.92million and 2000: 64% of 7.8 million = 4.99million; increase = 3.07 million; (Correct reading of all 4 figures from graph = 1) | 2 | |
| | | (Correct answer but no 'millions' = 1) (Correct method resulting from wrong graph reading = 1) | | |
| | | (ii) Over 50% of population being vaccinated; But only from 2000 onwards; (Principle of more people being vaccinated each year = 1) | 2 | |
| | | (iii) Different strain / type of virus each year / virus mutates; With different antigens; Influenza antibodies / memory cells (rapidly) destroyed / need replacing; | max 2 | |
| | (c) | (Protein coat) carries antigens which stimulates B-cells / production of antibodies; Production of memory cells; | | |
| | | | 2 | [9] |



| 14 | (a) | (i) | protein / glycoprotein / glycolipid / polysaccharide / molecule; on surface / membrane (of cell); causes immune response / description / triggers antibody | | |
|----|-----|-------|---|-------|-----|
| | | | production; | nax 2 | |
| | | (ii) | reference to hybrid cell from tumour / cancer and B-lymphocyte / hybridoma; antibodies all the same / from one type of plasma cell; specific to / complementary to / fits only one antigen; | nax 2 | |
| | (b) | (i) | antibodies specific / only binds to PSA; PSA only associated with prostate cancer / not with other diseases; | | |
| | | | | 2 | |
| | | (ii) | antibody with enzyme only attaches if PSA present / washed away if no PSA; no colour change without enzyme; | | |
| | | | no colour change without enzyme, | 2 | |
| | | | | | [8] |
| 15 | (a) | | ecule (on cell surface); triggers immune response; | | |
| | | that | | 2 | |
| | (b) | (i) | axes right way round and labelled; 2nd peak drawn higher; steeper gradient on second rise; | | |
| | | | | 3 | |
| | | (ii) | because one dose does not give a high enough level of antibody to be effective / because the antibody falls after a while; | 1 | |
| | | (iii) | antigens are only single molecules / part of parasite; do not actually cause disease; | • | |
| | | | | 2 | |
| | (c) | mala | ria sufferers would have parasites in red blood cells; | 1 | [9] |
| 16 | (a) | Resi | ence of resistant and non-resistant varieties / mutation produces resistant variety; stant ones survive / non-resistant ones killed by treatment; se will reproduce and produce more resistant parasites / pass on resistance allele; | 3 | 1 |
| | (b) | 1/50 | lihood of being infected (by strain resistant to both drugs) is less; 0 × 1/500/1/250 000; g has longer effective life; | | |



| (c) | (i) | As comparison / to show that nothing else in the treatment was responsible; | 1 | |
|-----|---------------|--|-------|------|
| | (ii) | Given injections of saline / injection without SPf66; (otherwise) treated the same as experimental group; | | |
| | | | 2 | |
| (d) | (i) | 100%; | 1 | |
| | (ii) | 10%; | 1 | |
| (e) | (i) | Different lengths of DNA have different base sequences / cut at specific sequence; | | |
| | | Results in different shape / different shape of active site; Therefore (specific sequence) will only fit active site of enzyme; | | |
| | (ii) | Recognition sites contain only AT pairs; | 3 | |
| | | Which would occur very frequently; | 2 | |
| | | | | [15] |
| (a) | inter shou | effects / allergic reactions / low toxicity to cells; action with other drugs / effective in conditions of use / reasonably stable; Ild only act on the problem bacteria / narrow spectrum; much resistance the bacteria have built up; | | |
| | now | | 2 max | |
| (b) | (i) | tetracycline prevents tRNA binding to ribosomes / amino acid / mRNA; | 1 | |
| | | amino acids not available / brought / picked up; | 1 | |
| | | chloramphenicol prevents <u>amino acids</u> being joined / prevents primary structure forming; | | |
| | | | 1 | |
| | | no enzymes / no structural proteins formed; (accept cell wall formation if qualified) (prevents protein synthesis gains one mark in either section, once only) | 1 | |
| | (ii) | only prevents tRNA binding to 70S / prokaryotic / bacterial ribosomes / human ribosomes are different sizes / shapes / structure; | 1 | |
| | | | 1 | [7] |

| | | EXAM PAPERS PRACTICE | |
|----|------|--|--|
| 18 | (a) | macrophages present antigens to B lymphocytes; antigen binds to / is complementary to receptors on lymphocyte; binds to a specific lymphocyte; lymphocytes become competent / sensitised; (B) lymphocytes reproduce by <u>mitosis</u> / (B) lymphocytes <u>cloned;</u> plasma cells secrete antibodies; | |
| | (b) | restriction enzyme / endonuclease; to cut plasmid / to form sticky ends in plasmid; (use) ligase(to join) <u>gene</u> to <u>plasmid</u>; culture bacteria with (in medium containing) plasmids to allow uptake of plasmids / transformation; use of cold shock / chemical treatment (to enhance uptake) / heat shock; (ignore bullets / electroporation / microinjection) | |
| | | 3 max | |
| 19 | (a) | bacteria have ligands / antigens / proteins / glycoproteins / polysaccharides (on membrane / wall); 1 | |
| | | complementary to receptors / fits / binds / attaches to specific receptor | |
| | (b) | enzymes denatured / tertiary / secondary structure altered / altered attered / active sites / breaks hydrogen bonds; | |
| | | 1 prevents named chemical reactions / metabolic pathways; 1 | |
| | (c) | inhibits / kills other bacteria / fungi / decomposers / reduces competition; | |
| | (d) | prepare a bacterial lawn / culture / sample; (accept mix bacteria with agar / medium) with oil and one with control / water / range of concentrations; appropriate method of standardising how sample applied, e.g. discs / wells; appropriate measure of effectiveness / size / diameter of clear zone; the larger the zone the greater the effectiveness; use of aseptic technique; | |
| | | (ignore haemocytometer) 4 max | |
| 20 | (i) | 1360 = 2 marks (general principle 0.68 ÷ 0.05 x 100 gains 1 mark) 2 | |
| | (ii) | still have maternal antibodies; | |

[3]

[9]

[7]



| 21 | (a) | (i) | fall in deaths due to rise in number of people with immunity / better care / targer vaccination at vulnerable; | ting | |
|----|-----|-------|---|-------|-----|
| | | | | 1 | |
| | | (ii) | mutation of virus / new strain; mutant form not recognised by memory cells (<i>allow antibodies</i>); | 2 max | |
| | (b) | (i) | T lymphocyte receptors recognise shape of haemagglutinin / neuraminidase / viral antigen; clone (<i>once only</i>); destroy virus; | | |
| | | | | 2 max | |
| | | (ii) | clone (<i>once only</i>); produce antibodies; effect of antibody e.g. stimulation of phagocytosis / | | |
| | | | precipitation of toxins; | 2 | |
| | (c) | | s shape of active site of neuraminidase / block active site; | | |
| | | | | 2 | [9] |
| 22 | (a) | antik | nory <u>B</u> / <u>T</u> cells do not recognise (new antigens); podies previously produced are not effective | | |
| | | as s | hape not complementary to new antigen; | 2 | |
| | (b) | (i) | <u>antigen</u> in <u>membrane</u> presented to lymphocytes / produce cytokinins; | | |
| | | | | 1 | |
| | | (ii) | mitochondria provide (more) ATP / energy; (more) RER / ribosomes synthesise proteins; (more) Calai hadv accentes (madified or peopleance proteins (| | |
| | | | (more) Golgi body secretes / modifies or packages proteins / produces glycoproteins; | | |
| | | | (B lymphocytes) produces antibodies; | 4 | |
| | | | | 4 | [7] |
| 23 | (a) | 47 2 | 13; | 1 | |
| | (b) | (i) | there is no difference in the proportion / number of influenza cases between the 5 vaccines; | | |
| | | | (reject vaccinated versus no vaccinated) | 1 | |
| | | (ii) | significant difference in proportion / number of cases of influenza between the vaccines / the null hypothesis should be rejected; | 1 | |
| | | | | 1 | |



| | (c) | sample size small; possible differences in exposure to infection; exposure to different strains / mutants; possible differences in existing immunity; possible differences in sex / age; possible differences in socio-economic status; | 2 max | [5] |
|----|-----|--|-------|-----|
| 24 | (a) | Microorganism alive/active; | | |
| | | But does not cause symptoms of disease/Avirulent; | | |
| | | Accept does not make you ill/harm | 2 | |
| | (b) | (i) (Takes time for) antigen to be recognised; | | |
| | () | Accept reference to presentation by macrophage for first marking point | | |
| | | (Takes time for) T cells to be activated; | | |
| | | Accept primary (immune) response | | |
| | | B-cell activation/clonal selection/expansion; Plasma cells to make (specific) antibodies; Time for enough antibodies to measure; | | |
| | | | 2 max | |
| | | (ii) Memory cells (present); | | |
| | | Accept secondary (immune) response | | |
| | | Respond immediately / can produce antibodies immediately; | 2 | [6] |
| | | | | [6] |
| 25 | (a) | Reverse transcriptase; Accept integrase/description of action of | | |
| | | Enzyme uses (HIV) RNA to make DNA (copy); | | |
| | | DNA joined to (host) cell's DNA/chromosome; | | |
| | | DNA used to make HIV RNA (copies); Accept (HIV) DNA replicated when (T) cell divides | | |
| | | And HIV capsid proteins/enzymes; | | |
| | | Made at (host) ribosomes; | | |
| | | Assembly of new virus particles; | | |
| | | Budding off from membrane (of host cell); | | |
| | | | 4 max | |



[6]

| (b) | Not enough/no T-cells to activate B-cells/lead to antibody production/ activate immune system; | |
|-----|---|-------|
| | Accept death of T-cells weakens the immune system | |
| | Person unable to fight /more prone to (opportunistic) infections/cancer; Accept diseases | |
| | Example of infection/cancer; | |
| | E.g. TB, pneumonia, cryptosporidium | 2 max |
| | | 2 max |
| (a) | Zevalin/antibody binds to specific receptor/cell surface protein/antigen; | |
| | (Only found) on B-cells; | |
| 4. | | 2 |
| (b) | Patient P treated with Zevalin/yttrium (no mark); Assume 'Zevalin' means 'with yttrium' unless they state | |
| | otherwise | |
| | Where indium/antibody (only) on lymphatic system/groin and armpits; | |
| | So only (cancerous) B-cells killed; | |
| | In patient P high concentration of radioactivity/antibodies high enough to kill cancer cells; | |
| | Patient Q – radioactivity in places where other body cells could be killed/ organs damaged/named example; | |
| | Could harm patient more than cancer; | |
| | Patient Q cancer has spread; | |
| | So too late to treat; | 3 max |
| (c) | Patient \mathbf{Q} – (cancerous) B-cells outside of lymphatic system/metastasis; | |
| | So antibody bound in other parts of the body (as well); | |
| | Patient ${f Q}$ – has different receptors/distribution of receptors compared to patient ${f P}$; | |
| | Other body cells (than B-cells) have receptors for antibody; | |
| | | 2 max |



(d) Might be allergic to mouse antibody/protein;

(Mouse) antibody acts as an antigen;

Causes an immune response/antibody production;

Antibody destroys Zevalin;

Releases radioactivity into body/prevents activity against the cancer;

27

(a)

Correct answer: 1.25; Ignore working

OR (if wrong answer)

 $\frac{\text{measurement in }\mu\text{m}}{40000} / \frac{\text{measurement in }\text{mm}}{40} = 1 \text{ mark}$

125 but wrong order of magnitude = 1 mark

(ii) **C** has myosin / thick (and actin / thin) filaments;

OR

A has only actin / thin (/ no myosin / no thick) filaments;

(b) When contracted:

Thick & thin filaments/myosin & actin overlap more;

Interaction between myosin heads & actin / cross-links form;

Movement of myosin head;

Thin filaments / actin moved along thick filaments / myosin;

Movement of thin filaments / actin pulls Z-lines closer together;

Displacement of tropomyosin to allow interaction;

Role of Ca^{2+} ;

Role of ATP;

Allow ref. to 'sliding filament mechanism' / described if no other marks awarded

4 max

2 max

2

1 max

[9]



8 has DMD but 3 and 4 do not / 12 has DMD but 6 and 7

(c)

(i)

| (C) | (1) | do not / neither parent has the condition but their child has; Allow parents 3 and 4 give 8, parents 6 and 7 give 12 | 1 |
|----------------|-------|--|---|
| | (ii) | 4 AND 7; | 1 |
| | (iii) | Parental genotypes: $6 = \mathbf{X}^{D}\mathbf{Y}$ AND $7 = \mathbf{X}^{D}\mathbf{X}^{d}$ | |
| | | AND | |
| | | Gametes correct for candidate's P genotypes – e.g. | |
| | | \mathbf{X}^{D} and $\mathbf{Y} + \mathbf{X}^{D}$ and \mathbf{X}^{d} ; | |
| | | Offspring genotypes correctly derived from gametes e.g. | |
| | | $\mathbf{X}^{\mathrm{D}}\mathbf{X}^{\mathrm{D}} + \mathbf{X}^{\mathrm{D}}\mathbf{X}^{\mathrm{d}} + \mathbf{X}^{\mathrm{D}}\mathbf{Y} + \mathbf{X}^{\mathrm{d}}\mathbf{Y};$ | |
| | | Male offspring with MD correctly identified: X ^d Y ; | |
| | | Probability = 0.25 / correct for candidates offsprings genotypes; Accept 1/4 / 1 in 4 / 1:3 / 25% NOT '3:1'/'1:4' | |
| (d) | (i) | No gene fragment G ; | 4 |
| | (ii) | Only one copy of gene fragment F ; | |
| | | Male has only one X-chromosome / is XY (c.f. female has two / is XX); | |
| | | | 2 |
| | (iii) | 10 has only one copy of gene fragment G ; | |
| | | 10 has only one normal X-chromosome / has one abnormal / has only one normal allele / has one X ^d / is X ^D X ^d / is heterozygous; | |
| | | 11 has two normal X-chromosomes / has 2 normal alleles / is $X^{D}X^{D}$ / has not got X^{d} / has 2 copies of (F and) G; | |
| (\mathbf{o}) | (i) | To prevent rejection / prevent antibody production vs. injected cells / | 3 |
| (e) | (i) | injected cells have (foreign) antigen (on surface); | 1 |
| | (ii) | Shows effect of <u>cells</u> / not just effect of injection / not just effect of salt solution; | 1 |
| | | | 1 |

| · · · · · · · · · · · · · · · · · · · | |
|---------------------------------------|---------|
| | RACTICE |
| | |

 (iii) Only one person tested so far – need more to see if similar results / need more to see if reliable;

Need to assess if new (dystrophin positive) muscle fibres are functional / if muscle becomes functional;

Can't tell how widespread effect is in the muscle / sample taken near injection site;

Need to test for harmful side effects;

Need to test if successful for other mutations of dystrophin gene;

Need to assess permanence / longevity of result/insufficient time allowed in investigation;

(In this patient) only small response / %;

Further sensible suggestion;

28

29

[25] P = membrane / lipid envelope / phospholipid bilayer; (a) (i) Q = reverse transcriptase; Accept (host) cell membrane; 2 (ii) Carries genetic information / to make DNA; Q Do not accept 'information' on its own Accept genes, alleles, to make (viral) protein; 1 (b) DNA copy made (of viral RNA); Inserted into host DNA / chromosomes; (Uses viral DNA to) make viral proteins/particles; Makes viral RNA; (Host) cell makes new viruses; "Budding off" / wrapped in cell membrane; Accept reverse transcriptase makes DNA for 2 marks in correct context: 3 max [6] (i) Molecule/protein/glycoprotein; (a) Stimulates immune response; (That causes) production of antibodies; 2 max Antigens on HIV are different (shape); (ii) So, antibody will not 'fit'/not complementary (to antigen);

2 max

4 max

Receptor sites on antibody specific to one antigen;



| | (iii) | (Has site with) same <u>shape</u> as salmonella antigen so binds to anti-gal antibodies; (Has site with) same <u>shape</u> as receptor molecule so that HIV will bind; Binds to both molecules; | 2 max | | |
|------|---|---|-------|--|--|
| (b) | Salr T-ce B-ce clon B-ce <u>Plas</u> | nonella pathogen has specific antigen on surface; nonella pathogen engulfed by macrophage; ells activate B-cells; ell with complementary/specific receptor antibody activated/ al selection; ells divide/form clone/clonal expansion; ema cells make antibodies; cific to antigen/bind to salmonella bacterial antigen; <i>Accept macrophage presents antigen to T/B cells;</i> <i>Accept T-cells release factors;</i> | 6 | | |
| | (;) | LIN/ binds to specific recentory | 6 max | | |
| (c) | (i) | HIV binds to specific receptor; Only present on certain cells / T-cells; | 2 | | |
| | (ii) | Antibiotics stop metabolism, viruses don't have metabolism; Viruses hide in cells, antibiotics can't reach; | | | |
| | | Two suitable cell components antibiotics work against that viruses don't have; e.g. some antibiotics work against ribosomes, that viruses don't have | | | |
| (1) | <i>(</i>) | • • • • • • • • • • • • • | 2 | | |
| (d) | (i) | Adaptor molecule binds to HIV; (This) prevents the HIV binding to the receptor; Therefore few HIV available to infect cells; | | | |
| | | | 2 max | | |
| | (ii) | Would need to be complementary to MRSA (antigens); MRSA has different antigens; But would still need to have binding site for anti-gal; | | | |
| | | | 2 max | | |
| (a) | (a) Protein / molecule/glycoprotein; On surface of cell/microorganism; Stimulates immune response/production of antibodies; | | | | |
| | | | | | |

[20]



 (b) Zookeeper is not producing antibodies/passive immunity; No memory cells made;

OR

Antivenom is an antigen/stimulates production of (anti-antivenom) antibodies; (Antivenom) destroyed by zookeeper's own antibodies;

OR

Antibody destroys antigen/venom; Before immune response/no immune response;

- (a) Cotinine is an antigen; Antigen/cotinine binds to (specific) T-cell/activates T-cell; T-cell activates B-cells; Specific B cell becomes activated; (Specific) B cell divides/ clonal expansion; Forms (clone of) plasma cells; (Plasma) cell produces antibodies; Accept macrophage presents antigen for one mark Ignore references to memory cells and secondary immune response
 4 max
 - Antibodies are proteins with tertiary structure/specific shape/binding sites;
 Antibodies specific shape for cotinine;
 Only cotinine fits;

Do not credit active site

[6]

2

2

[4]



- (a) Damage / destruction of cells / tissues; Production of toxins;
 - (b) Contains antigen / proteins / dead / weakened microorganism / pathogen / virus / bacteria;
 Stimulates production of antibodies / plasma cells / memory cells;
 Q Do not credit immune response unless qualified.
 - (c) (i) Age;

Sex;

Ethnicity;

All healthy / not on other medication;

Not previously vaccinated / infected with TB;

Q Do not credit sample size.

Q Allow any suitable reference to health not being affected for fourth marking point e.g. smoking, 'depressed immune system' etc.

2 max

1

2

2

(ii) Contain the same antigens;

[7]